• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

European Society for Medical Oncology (ESMO) 2021

September 16-21, 2021

  1. Adavosertib
  2. Fulvestrant
  3. Olaparib
  4. Datopotamab Deruxtecan
  5. Durvalumab
  6. Osimertinib
  7. Trastuzumab Deruxtecan

Html

Inhibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): A randomised phase II trial (FOCUS4-C) comparing Adavosertib (AZD1775) with active monitoring

Html

CAPItello-292: a phase 1b/3 study of capivasertib, palbociclib and fulvestrant versus placebo, palbociclib and fulvestrant in HR+/HER2− advanced breast cancer

Html

Overall Survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs). Final results of the PEARL study

Html

Exploring the interplay between tumor burden and liquid biopsy longitudinal evaluation in Hormone Receptor-positive, HER2-negative metastatic breast cancer (MBC)

Html

Interim results from a phase 2 study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies

Html

ENGOT/GYN1/NCRI: ATR inhibitor in combination with olaparib in gynaecological cancers with ARID1A loss or no loss (ATARI)

Html

Retreatment with maintenance olaparib in patients (pts) with ovarian cancer (OC) previously treated with a PARP inhibitor (PARPi): randomized Phase IIIb OReO/ENGOT Ov-38 trial

Html

Bipolar Androgen Therapy (BAT) plus Olaparib in Men with Metastatic Castration-resistant Prostate Cancer (mCRPC)

Pdf

Concordance between multiple HRD assays is substantial in high grade ovarian cancer

Pdf

Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial

Html

Efficacy of olaparib in advanced cancers occurring in patients with germline or somatic tumor mutations in homologous recombination (HR) genes, a Belgian Precision study

Html

Multi-maintenance olaparib in relapsed, platinum-sensitive BRCA-mutant high-grade serous ovarian carcinoma (MOLTO): a phase II feasibility study

Html

Neutrophil-Lymphocyte ratio predicts survival in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD): stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601

Pdf

Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): exploratory biomarker analyses of the Phase IIIb OPINION study

Html

ORCA-2: A Phase I Study of Olaparib in Addition to Cisplatin-Based Concurrent Chemoradiotherapy for Patients with High Risk Locally Advanced (LA) Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Pdf

POLO: Long-term safety and tolerability of olaparib for patients with a germline BRCA mutation and metastatic pancreatic cancer

Pdf

POLO: subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer

Html

A phase I trial of Durvalumab (Durv) in combination with Olaparib (Ola) and Capivasertib  (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)

Html

Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase 3 study of olaparib or combination cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer: biomarker analyses from NRG-GY004.

Html

Randomised Phase II Trial of Olaparib compared to weekly paclitaxel or Olaparib plus Cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)

Html

Bevacizumab (Bev), Olaparib (Ola) and Durvalumab (Durva) in patients with recurrent Advanced Ovarian Cancer (AOC): the GINECO BOLD study.

Html

Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): preliminary results from the phase 1 TROPION-PanTumor01 study

Pdf

PACIFIC-R Real-World Study: Treatment Duration and Interim Analysis of Progression-Free Survival in Unresectable Stage III NSCLC Patients Treated with Durvalumab After Chemoradiotherapy

Html

Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in IFCT-1601 IONESCO phase 2 trial.

Html

Spatial Distribution of CD8+ and FoxP3+ in a Window of Opportunity for Durvalumab (MEDI4736) plus Metformin Trial in Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Pdf

Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy (IO) vs chemotherapy (CT) in patients with 1L metastatic (m) NSCLC: analyses from the Phase 3 MYSTIC trial

Html

Real-world Treatment Patterns and Outcomes in Stage III Non-small Cell Lung Cancer (NSCLC): Middle East and Africa (MEA)-KINDLE Study

Html

The Impact of COVID-19 Pandemic on Spanish Genitourinary (GU) Cancer Patients. SOGUG-COVID-19 study

Html

Durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CANTABRICO): a Spanish phase IIIb single arm, real world study

Pdf

COAST: an open-label, phase 2, multidrug platform study of durvalumab alone or in combination with novel agents in patients with unresectable, Stage III NSCLC

Html

Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)

Html

Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC)

Pdf

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the Phase 3 CASPIAN study

Pdf

Durvalumab and tremelimumab in combination with FOLFOX in patients with previously untreated RAS-mutated metastatic colorectal cancer: First results of efficacy at one year for phase II MEDITREME trial.

Html

Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601)

Html

Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): efficacy and safety results of the advanced breast cancer (ABC) patients (pts) cohort of the MOVIE study.

Pdf

PD-L1 as a predictor of survival in patients with metastatic urothelial carcinoma (mUC) from the phase 3 DANUBE trial of durvalumab (D) or durvalumab plus tremelimumab (D+T) versus standard of care chemotherapy (SoC)

Html

Phase Ib INEOV neoadjuvant trial of the anti-PDL1, durvalumab (D) +/- anti-CTLA4 tremelimumab (T) with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC):a GINECO study

Html

Tremelimumab (T) + durvalumab (D) combined with metronomic oral vinorelbine (MOV): results of the recurrent cervical cancer (RCC) cohort of the MOVIE study.

Html

Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small-cell lung cancer harboring EGFR mutations; WJOG9717L study

Html

AUTOMAN: A phase Ib/IIa study of Osimertinib combined with Anlotinib in EGFRm, treatment-naive advanced NSCLC patients.

Html

Clinical Utility of Liquid Biopsy for the Early Diagnosis of EGFR Mutant Advanced Lung Cancer in a Real-life Setting (CLEAR)

Html

High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: results from a phase 2 multicenter study, POSITION20

Html

Induction Osimertinib in EGFR-mutant stage IIIA/B NSCLC

Pdf

Modelling long-term survival outcomes in patients with stage (stg) IB–IIIA EGFR-mutated NSCLC from the ADAURA trial

Pdf

ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed Phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib

Pdf

Real world outcomes in resected stage IB-IIIA EGFR mutated NSCLC in Canada: Analysis from the POTENT study

Html

UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first liNe setting (UNICORN)

Pdf

Real-world EGFR and T790M testing patterns in patients from Central Eastern Europe with advanced Non-Small Cell Lung Cancer - results from a large retrospective study (REFLECT)

Pdf

Real-world treatment patterns and clinical outcomes in patients from Central Eastern Europe with EGFR-mutated advanced Non-Small Cell Lung Cancer - results from a large retrospective study (REFLECT)

Pdf

Exploratory Biomarker Analysis of DESTINY-CRC01, a Phase 2, Multicenter, Open-Label Study of Trastuzumab Deruxtecan (T-DXd, DS-8201) in Patients (pts) With HER2-Expressing Metastatic Colorectal Cancer (mCRC)

Pdf

Primary Analysis of a Phase 2 Single-Arm Trial of Trastuzumab Deruxtecan (T-DXd) in Western Patients With HER2-Positive (HER2+) Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Cancer Who Progressed on or After a Trastuzumab-containing Regimen

Pdf

Primary Data from DESTINY-Lung01: A Phase 2 Trial of Trastuzumab Deruxtecan (T-DXd) in Patients (Pts) With HER2-Mutated (HER2m) Metastatic Non-Small Cell Lung Cancer (NSCLC)

Pdf

Trastuzumab Deruxtecan (T-DXd) vs Trastuzumab Emtansine (T-DM1) in Patients (Pts) With HER2+ Metastatic Breast Cancer (mBC): Results of the Randomized, Phase 3 Study DESTINY-Breast03

Pdf

A retrospective population-based observational study in metastatic HER2-positive breast cancer patients in Denmark previously treated with T-DM1

Pdf

Burden of Illness of HER2+ in Metastatic Breast Cancer (MBC) Patients: A Systematic Literature Review (SLR)

Html

Co-clinical PDX study of trastuzumab deruxtecan in HER2-positive uterine carcinosarcoma (STATICE TRIAL, NCCH1615)

Html

Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE TRIAL, NCCH1615): A MULTICENTER, PHASE 2 CLINICAL TRIAL

Html

Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: results from the first stage of the phase II TUXEDO-1 trial

Pdf

Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Metastatic Breast Cancer (MBC): Updated Survival Results from a Phase 2 Trial (DESTINY-Breast01)

Pdf

A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select HER2-expressing solid tumors (DESTINY-PanTumor02)

Pdf

Open-label, multinational, multicenter, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer (HER2+ BC): DESTINY-Breast12

Pdf

Phase 3 study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09

Pdf

Trastuzumab Deruxtecan (T-DXd) in Patients (pts) with HER2-Mutated (HER2m) Metastatic Non-Small Cell Lung Cancer (NSCLC): A Phase (ph) 2 Study (DESTINY-Lung02)

Pdf

Trastuzumab Deruxtecan (T-DXd) in Patients (Pts) With HER2-Positive Gastric Cancer (GC) or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Progressed On or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04, DG-04): A Randomized Phase 3 Study

Need Help?

Contact Us

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. Med Co has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice